Revenue showed an overall increasing trend. The pharmaceuticals segment was the main driver, led by key products Lenvima, Rekembi, and Dayvigo. Currency effects contributed to revenue and profit; core operating profit increased. Progress toward the full-year forecast is high at the 50% range.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4523-20261110-02.pdf","jir_short_summary":"Revenue showed an overall increasing trend. The pharmaceuticals segment was the main driver, led by key products Lenvima, Rekembi, and Dayvigo. Currency effects contributed to revenue and profit; core operating profit increased. Progress toward the full-year forecast is high at the 50% range.","jir_summary":"### Overview of Results\nFor the second quarter of fiscal 2026, revenue was 4,700 hundred million yen, operating income was 414 hundred million yen, and core operating profit was 431 hundred million yen, all increasing year-over-year. The pharmaceuticals business performed well, with strong contributions from key products such as Lenvima, Rekembi, and Dayvigo. Growth was also achieved on a constant-currency basis excluding foreign exchange effects. The full-year forecast is revenue of 8,835 hundred million yen, with a progress rate of 53.2% toward the full-year target.\n\n### Segment Highlights and Outlook\nThe pharmaceuticals segment contributed approximately 8,621 hundred million yen in revenue. Major products in Japan, the U.S., China, EMEA, and EAGS continued to perform solidly. In particular, contributions from Lenvima, Dayvigo, and Rekembi remain important, and overall revenue growth considering currency impacts continues to be significant. Going forward, attention will be paid to trends with sensitivity to foreign exchange rates.","jir_financial_highlights":"Revenue: 4,700 (Half-year results, unit: hundred million yen) (Year-over-Year change: 17.5% increase (excluding currency effects: 9.2%))\nOperating Income: 414 (Year-over-Year change: 20.4% increase)\nCore Operating Profit: 431 (Year-over-Year change: 28.6% increase)\nProfit for the Half-Year (Net Income): 313 (Year-over-Year change: 20.9% increase)\nROE: \u2013 (Unknown)","jir_category":"","jir_hashtags":"#Eisai, #FinancialResults, #PharmaceuticalsBusiness, #CurrencyImpact","jir_key_figures":"Revenue: 4,700 (Half-year results)\nOperating Income: 414\nCore Operating Profit: 431\nProfit for the Half-Year (Net Income): 313\nProgress vs Full-Year Forecast: 53.2% (Full-year 8,835)","jir_meta_title":"Eisai Co., Ltd. Fiscal 2026 Q2 Financial Results | Revenue 4,700 hundred million yen, Operating Income 414 hundred million yen","jir_meta_description":"Summary of Eisai Co., Ltd.'s fiscal 2026 Q2 financial results: revenue 4,700 hundred million yen, operating income 414 hundred million yen, core operating profit 431 hundred million yen. Includes segment breakdown and progress toward the full-year forecast, with discussion of currency impacts.","jir_og_title":"Eisai Q2 Financial Results: Revenue and Profit Exceed Prior Year","jir_og_description":"Eisai Co., Ltd.'s fiscal 2026 Q2 results: revenue 4,700 hundred million yen, operating income 414 hundred million yen, core operating profit 431 hundred million yen. Detailed contributions from key drugs and full-year progress.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q2\\\",\\\"FY2026 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[4000,4700]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q2\\\",\\\"FY2026 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[344,414]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"core_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q2\\\",\\\"FY2026 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Profit\\\",\\\"data\\\":[335,431]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Reported Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals Business\\\",\\\"Other Businesses\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[4621,79]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Comparison of Guidance and Results\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Half-year Results\\\",\\\"Full-year Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[4700,8835]}]},\\\"options\\\":{}}\"}]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-147177","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n